Magnitude Of Effect, Not Survival, Is Key To Approval For Oncologic Nexavar
Executive Summary
Sponsors of oncology agents should select endpoints where a drug is likely to have a "magnitude of effect" instead of focusing on survival, FDA said following its Dec. 20 approval of Bayer/Onyx' kidney cancer therapy Nexavar (sorafenib)
You may also be interested in...
FDA Needs To Put Meaning Behind “Clinically Meaningful,” Lipicky Says
FDA's increasing requirements for clinical meaningfulness in efficacy measures make it more difficult to predict the agency's regulatory actions, former division director Ray Lipicky says
FDA Needs To Put Meaning Behind “Clinically Meaningful,” Lipicky Says
FDA's increasing requirements for clinical meaningfulness in efficacy measures make it more difficult to predict the agency's regulatory actions, former division director Ray Lipicky says
Oncologic Accelerated Approval Best Based On Pivotal Trial Interim Analysis
FDA is encouraging sponsors to use data from an interim analysis of an ongoing pivotal trial to support accelerated approval of cancer products, rather than relying on separate postmarketing studies